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Repeat-Associated Non-AUG Translation
from Antisense CCG Repeats in
Fragile X Tremor/Ataxia Syndrome
Amy Krans, MS,1,2 Michael G. Kearse, PhD,1 and Peter K. Todd, MD, PhD1,2
Objective: Repeat-associated non-AUG (RAN) translation drives production of toxic proteins from pathogenic repeat
sequences in multiple untreatable neurodegenerative disorders. Fragile X-associated tremor/ataxia syndrome (FXTAS)
is one such condition, resulting from a CGG trinucleotide repeat expansion in the 50 leader sequence of the FMR1 gene.
RAN proteins from the CGG repeat accumulate in ubiquitinated inclusions in FXTAS patient brains and elicit toxicity. In
addition to the CGG repeat, an antisense mRNA containing a CCG repeat is also transcribed from the FMR1 locus. We
evaluated whether this antisense CCG repeat supports RAN translation and contributes to pathology in FXTAS patients.
Methods: We generated a series of CCG RAN translation-specific reporters and utilized them to measure RAN trans-
lation from CCG repeats in multiple reading frames in transfected cells. We also developed antibodies against pre-
dicted CCG RAN proteins and used immunohistochemistry and immunofluorescence on FXTAS patient tissues to
measure their accumulation and distribution.
Results: RAN translation from CCG repeats is supported in all 3 potential reading frames, generating polyproline,
polyarginine, and polyalanine proteins, respectively. Their production occurs whether or not the natural AUG start
upstream of the repeat in the proline reading frame is present. All 3 frames show greater translation at larger repeat
sizes. Antibodies targeted to the antisense FMR polyproline and polyalanine proteins selectively stain nuclear and
cytoplasmic aggregates in FXTAS patients and colocalize with ubiquitinated neuronal inclusions.
Interpretation: RAN translation from antisense CCG repeats generates novel proteins that accumulate in ubiquiti-
nated inclusions in FXTAS patients.
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Nucleotide repeat expansions are among the mostcommon inherited causes of neurodegeneration and
neurological disease.1 These progressive disorders are cur-
rently without any effective treatment. Repeat expansions
elicit toxicity through a range of different pathogenic
mechanisms, including polyglutamine-mediated aggrega-
tion and associated impairment of protein quality control
pathways, RNA repeat-mediated sequestration of protein-
bound factors, and DNA-mediated transcriptional silenc-
ing of the genes in which they reside.2–4
Work by a number of groups has recently demon-
strated that expanded nucleotide repeats can also
support an unusual form of protein translational initia-
tion known as repeat-associated non-AUG (RAN) trans-
lation.5,6 RAN translation allows for production of
aberrant homopolymeric or dipeptide repeat proteins in
the absence of an AUG start codon. It has now been
described at CAG, CUG, GGGGCC, CCCCGG, and
CGG repeats.5,7–13 RAN proteins can be generated from
multiple reading frames of the same repeat, and in disor-
ders where bidirectional transcription through the repeat
is present, RAN translation can also occur on the anti-
sense transcript, leading to a series of potentially toxic
products that accumulate in patient neurons.5,6,9,10,12
Fragile X-associated tremor/ataxia syndrome (FXTAS)
is an age-related neurodegenerative disease caused by a
CGG trinucleotide repeat expansion in the 50 untranslated
region (hereafter referred to as the 50 leader sequence) of the
FMR1 gene.14 FXTAS is under-recognized clinically, with a
predicted incidence of 1:3,000 men older than 50 years.15
Clinical characteristics include progressive gait ataxia, inten-
tion tremor, parkinsonism, and dementia.16 FXTAS patients
and animals models of disease are characterized by elevated
FMR1 mRNA levels, decreased levels of the fragile X
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protein, FMRP, and intranuclear ubiquitinated neuronal
inclusions in the cerebellum and other brain regions.14,17,18
Our group previously demonstrated that RAN
translation occurs on CGG repeats in FXTAS to produce
homopolymeric polyglycine (FMRpolyG) and polyala-
nine (FMRpolyA) proteins.7 FMRpolyG proteins aggre-
gate in cellular, fly, and mouse models of FXTAS and in
ubiquitinated inclusions in patient brain tissue, and
FMRpolyG production drives CGG repeat toxicity in
simple model systems.7,19 The FMR1 locus also produces
an antisense transcript, ASFMR1, that contains an anti-
sense CCG repeat.20,21 This antisense repeat lies within a
putative open reading frame, that if utilized would gener-
ate a short polyproline-containing protein, ASFMRP.20
ASFMR1 mRNA is ubiquitously expressed in human tis-
sue, with highest expression in the brain, and its expres-
sion is elevated in FXTAS patients and models.20
Because the CCG repeat in the ASFMR1 transcript is
predicted to form a stable secondary structure,22 we
hypothesized that it might support RAN translation and
potentially contribute to disease pathogenesis in FXTAS,
similar to the CGG repeat in the sense transcript.23
Here, we provide evidence from cellular models that the
CCG repeat can support RAN translation in all 3 read-
ing frames to produce homopolymeric proteins. We fur-
ther demonstrate that antibodies generated against the
predicted proline (ASFMRpolyP) and alanine (ASFMR-
polyA) RAN products stain ubiquitinated neuronal inclu-
sions in FXTAS patients. These data suggest a role for




The base constructs and cloning strategies used were previously
described.24 Briefly, each frame of ASFMR1 was cloned into
GGG-NL-3xFLAG pcDNA by 2 rounds of Q5 site-directed
mutagenesis (New England BioLabs, Ipswich, MA) followed by
2 rounds of annealing primer ligation using XhoI and EcoRV,
and NarI and EcoRV restriction sites, respectively. All constructs
were verified by Sanger sequencing. Expanded repeats were
inserted using XhoI and NarI from FMRpolyG100 green fluo-
rescent protein (GFP).7 Repeat sizes were determined by restric-
tion digest. Primer and construct sequences are available upon
request.
Western Blotting
COS-7 cells were transfected with reporter constructs using
Lipofectamine LTX with Plus reagent (Thermo Fisher Scientif-
ic, Waltham, MA) according to the manufacturer’s protocol.
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
Western blotting were done at 24 hours after transfection as
described previously.7,24 For analysis of tagged constructs,
membranes were incubated with mouse monoclonal FLAG-M2
(1:1,000; Sigma, St Louis, MO; F1804) and mouse monoclonal
glyceraldehyde-3-phosphate dehydrogenase (1:1,000; Santa
Cruz Biotechnology, Santa Cruz, CA; sc32233) overnight at
48C. Detection was performed using Western Lightning ECL-
Plus (PerkinElmer, Waltham, MA) on autoradiography film.
AUG-nanoluciferase-3xFLAG (AUG-NL) was loaded at one-
tenth the amount of the other reporters to avoid overexposure
on the film.
Luciferase Assay
COS-7 cells were plated on a 96-well tissue culture plate and
were cotransfected with ASFMR1 reporter constructs and
pGL4.13 (Firefly luciferase; Promega, Madison, WI) using Via-
fect (Promega) according to the manufacturer’s protocol. Lucif-
erase assays were performed at 24 hours after transfection as
previously described.24 Nanoluciferase (NL) signal was normal-
ized to the internal Firefly luciferase control. Each experiment
included 3 technical replicates averaged to generate a single “n”.
All experiments were carried out at least in triplicate. Experi-
mental results were analyzed by 1-way analysis of variance using
Prism (GraphPad, San Diego, CA). Significance of the differ-
ence between individual constructs was determined by Fisher
least significant difference with Bonferroni correction for multi-
ple comparisons.
Generation of Polyclonal Antibodies
Rabbit polyclonal antibodies were generated by NeoScientific
(Cambridge, MA) to synthetic peptides corresponding to the
repeat and C-terminal sequence of the predicted proteins (exact
epitopes are shown in Fig 1). Antisera were affinity purified
using the respective peptide immunogens. Preimmune sera were
used as a negative control.
Immunocytochemistry
COS-7 cells were grown on 4-well chamber slides and trans-
fected with Lipofectamine LTX with Plus reagent. Twenty-four
hours after transfection, cells were fixed with 4% paraformalde-
hyde, permeabilized with 0.1% Triton-X in phosphate-buffered
saline, 1mM MgCl2, 0.1mM CaCl2 (PBS-MC), and then
blocked in 5% normal goat serum (NGS) in PBS-MC for 1
hour at room temperature. Incubation with primary antibodies
(FLAG-M2, 1:100, Sigma; ASpolyP, 1:50, NeoScientific;
ASpolyA, 1:10, NeoScientific; Nucleolin, 1:500, Abcam
[Cambridge, MA], ab22758) diluted in 5% NGS in PBS-MC
was done overnight at 48C. After rinsing cells with PBS-MC,
slides were incubated with goat antimouse and goat antirabbit
IgG antibodies conjugated with Alexa 488 and Alexa 555,
respectively (1:500 each, Thermo Fisher Scientific, A11029 and
A21428, respectively) for 1 hour at room temperature. Slides
were washed, and coverslips were mounted with Prolong Gold
with DAPI (Thermo Fisher Scientific). Images were captured
on an inverted Olympus (Tokyo, Japan) IX71 microscope at
the same exposure and processed using SlideBook 5.5 software,
with changes in brightness and contrast applied to the whole
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image and identically to all images used in a given figure
according to published standards.25
Immunohistochemistry and
Coimmunofluorescence
Control and FXTAS autopsy tissue was obtained from the Uni-
versity of Michigan Brain Bank and the New York Brain Bank
with informed consent of patients or their relatives and approval
of local institutional review boards. Two of the FXTAS cases were
previously described.26 The third case had parkinsonism, progres-
sive gait difficulties, and dementia with onset in his 70s. Autopsy
showed ubiquitinated inclusions in his brainstem, hippocampus,
and cortex with rare Lewy bodies in the substantia nigra (data not
shown). Tissue sections were processed as previously described.7
For immunohistochemistry, primary antibodies (ASpolyA, 1:10;
ASpolyP, 1:100; ubiquitin, 1:250, Dako [Carpinteria, CA],
Z0458) were diluted in 5% NGS in Tris, pH 7.6, 0.1% Triton X-
100, 0.5% bovine serum albumin and incubated overnight at
48C. Antigen retrieval was required for some antibodies
(ubiquitin: 0.1mM sodium citrate, pH 8, 10 minutes at 808C;
ASpolyA: 0.1mM sodium citrate, pH 6, 5 minutes at 808C). For
coimmunofluorescence studies with ubiquitin, primary anti-
bodies (ubiquitin, 1:250, Millipore [Billerica, MA], MAB1510
with ASpolyA, 1:10 or ASpolyP, 1:50) were incubated overnight
at 48C with 5% NGS in PBS-MC, and incubated with goat anti-
rabbit and goat antimouse IgG antibodies conjugated with Alexa
488 and Alexa 635, respectively (1:500, Thermo Fisher Scientific,
A11008 and A31574, respectively). Images were captured on an
Olympus confocal microscope, compiled using ImageJ, and ana-
lyzed as previously described.7
Results
The FMR1 locus is bidirectionally transcribed under both
normal and pathological conditions (see Fig 1).20,21 The
antisense transcript, ASFMR1, has multiple promoters and
alternative splice isoforms. One isoform, ASFMR1a,
includes a region of the second intron and exon of FMR1
fused by alternative splicing to 500 nucleotides of exon
FIGURE 1: ASFMR1 transcript and putative repeat-associated non-AUG (RAN) translation products. (A) The FMR1 locus is bidi-
rectionally transcribed with a start site (TSS) between exons 2 and 3 in the antisense orientation. ASFMR1a mRNA includes an
AUG start codon upstream of the CCG repeat, creating a polyproline-containing open reading frame (ASFMRP). RAN transla-
tion of ASFMR1a mRNA could result in proline (10 reading frame, ASFMRpolyP), arginine (11, ASFMRpolyR), and alanine (12,
ASFMRpolyA) repeat proteins. Underlined regions are epitopes used for antibody generation. (B) ASFMR1 RAN-specific report-
ers contain the ASFMR1 mRNA sequence including the repeat upstream of a C-terminally 3xFLAG-tagged nanoluciferase lack-
ing a start codon (GGG-NL). Expression constructs were generated for each reading frame by addition of nucleotide
frameshifts (1/2FS) at different CCG repeat lengths and with or without the AUG start codon for ASFMRP (1/2AUG).
CMV 5 cytomegalovirus promoter.
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1 extending past the annotated transcription start site of
FMR1.20 ASFMR1a transcripts include the 50 leader
sequence of FMR1 and the repeat in a CCG orientation.
This transcript has a predicted open reading frame with
an AUG start codon that includes the repeat in the poly-
proline reading frame (ASFMRP; see Fig 1A).20 If RAN
translation of ASFMR1a mRNA were to occur upstream
of the repeat, it would produce 3 different repeat proteins:
ASFMRpolyP, a polyproline protein derived from the
same CCG (10) reading frame as ASFMRP; ASFMRpo-
lyR, a polyarginine protein from the CGC (11) reading
frame; and ASFMRpolyA, a polyalanine protein from the
GCC (12) reading frame.
To evaluate whether CCG repeats in the context of
the ASFMR1a transcript can support RAN translation, we
generated a series of CCG RAN translation-specific NL
reporters tagged with a carboxy-terminal 3xFLAG epitope
to allow for easy detection by Western blot and immuno-
cytochemistry and quantification by luciferase activity (see
Fig 1B).24 To assure that the reporter only provided signal
if initiation occurred within the ASFMR1 sequence, we
mutated the AUG start codon of NL to GGG, which elim-
inated most of its translation and luciferase activity.24 We
then cloned the ASFMR1a sequence upstream of the modi-
fied NL coding sequence. Two sets of constructs were gen-
erated. One set retained the native AUG start codon
naturally present in ASFMR1, and a second set was gener-
ated where this AUG was removed (see Fig 1B). In addi-
tion, frameshifts were introduced below the repeat such
that the NL coding sequence would be in frame for each of
the 3 different potential RAN products, creating repeat
protein–luciferase fusions. We also generated constructs
with a range of repeat sizes, from the normal range in
humans (25 repeats) up into the pathologic repeat size in
FXTAS patients (>55 repeats).
AUG-NL expressed by transient transfection in
COS-7 cells ran as a single band of 18kD by Western
blot analysis of the 3X-FLAG tag (Fig 2). Mutation of this
start codon to GGG led to a marked reduction in NL pro-
duction and luciferase signal.24 When the ASFMR1
sequence was introduced above GGG NL in the 10 (pro-
line) reading frame, higher molecular weight products
were detected that increased in size with increasing CCG
repeat length, consistent with translation initiating in
ASFMR1 above the repeat. To determine whether RAN
translation could occur, the natural upstream AUG start
codon initiating ASFMRP was removed. This change
markedly decreased the higher molecular weight protein
products in constructs lacking the CCG repeat or with a
normal repeat size (30 CGG repeats). However, at larger
repeat sizes (>40 CGG repeats) these higher molecular
weight species persisted in the absence of the AUG codon,
with enhanced abundance with increasing repeat size as
measured by luciferase activity, consistent with RAN trans-
lational initiation.
To determine the subcellular distribution of these
novel polyproline-containing proteins, we performed
immunofluorescence against the FLAG tag epitope in
transfected cells (see Fig 2C). AUG-initiated ASFMRP
fused to NL was distributed throughout the cytoplasm and
nucleus in a pattern that was similar to AUG-NL alone.
Neither increasing repeat size nor the removal of the AUG
start codon significantly altered this distribution.
We next tested whether RAN translation could occur
in the other 2 potential repeat reading frames (CGC, argi-
nine and GCC, alanine). When the GGG-NL reporter
was placed in the 11 (arginine) reading frame, we
observed a higher molecular weight species by Western
blot that increased with increasing repeat number and
formed large (>150kD) complexes at higher repeat sizes,
consistent with published reports of arginine-containing
RAN proteins (Fig 3).8,11 This product was generated and
present regardless of whether the AUG codon normally in
the proline reading frame was present or removed (see
Fig 3A, noATG). As with ASFMRpolyP, translation of
ASFMRpolyR was enhanced at increasing repeat sizes.
Unlike the staining pattern of ASFMRpolyP, ASFMRpo-
lyR exhibited a clear redistribution in its intracellular stain-
ing pattern that was dependent on the arginine repeat,
such that at normal and expanded repeat numbers, the
protein localized to the nucleolus. This change in localiza-
tion was confirmed by coimmunofluorescence with the
nucleolar marker nucleolin and is consistent with findings
reported for dipeptide repeat-containing RAN products
generated in C9orf72.27,28
In the third (12, alanine, GCC) potential reading
frame, a similar pattern was observed (Fig 4). Translation
of higher molecular weight species were observed in this
reading frame in both the presence and absence of the
repeat. Mutational analysis demonstrated that in the
absence of any repeat, initiation occurred predominantly
below the repeat at 2 different near-AUG codons found
in the human sequence (see Fig 4A and data not shown).
Initiation at these sites did not significantly increase the
luciferase signal above that of our negative control con-
struct. However, at increasing repeat sizes, an additional
higher molecular weight product appeared that increased
in size in line with repeat number. At> 50 CCG repeats,
products accumulated as a large complex (>150kD) near
the top of the gel. ASFMRpolyA abundance increased
with addition of repeats and was greatest at the largest
repeat sizes. ASFMRpolyA production was significantly
suppressed by inclusion of the upstream AUG codon in
the proline reading frame in the absence of any repeat or
ANNALS of Neurology
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at normal repeat sizes, but not at expanded repeats. This
alanine translation product, ASFMRpolyA, exhibited a
clear change in its cellular distribution in transfected cells
compared to AUG-NL alone, with a repeat length-
dependent redistribution into the nucleus.
If RAN translation products from ASFMR1a mRNA
are generated in vivo, then we would predict that we
should be able to identify them in FXTAS patients. To test
this hypothesis, we generated a series of polyclonal anti-
bodies against short stretches of the predicted repeats and
the C-terminal portion of the predicted proteins (see Fig
1A, underlined region of protein sequences). To assess the
specificity of these antibodies, we performed Western blot-
ting and immunofluorescence on cells expressing the
appropriate RAN translation product or control constructs
lacking the 50 leader sequence. Both the ASFMRpolyP-
specific and ASFMRpolyA-specific antibodies exhibited
specificity for their cognate RAN protein by Western blot
(Fig 5A, C) and by immunofluorescence (see Fig 5B, D),
respectively. Unfortunately, despite multiple attempts and
use of different epitopes, antibodies generated against the
predicted ASFMRpolyR protein failed to exhibit sufficient
specificity in these validation assays to support further test-
ing in human tissues (data not shown).
FIGURE 2: Repeat-associated non-AUG (RAN) translation from CCG repeats in the proline reading frame of ASFMR1. (A) Anti-
FLAG Western blot of whole cell lysates from COS-7 cells transfected with the indicated reporters for ASFMRP and ASFMRpo-
lyP. Molecular weight of ASFMR1-derived proteins increased with expanded repeats (ATG Px). Removal of the AUG start codon
for ASFMRP (noATG Px, left) eliminated these proteins in the absence of a repeat, but did not prevent their generation at larg-
er repeat sizes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control and AUG-nanoluciferase (NL)
and GGG-NL served as positive and negative controls, respectively. (B) NL activity from indicated constructs. For all figures,
the Y axis shows mean 6 standard deviation expressed as fold change above GGG-NL (n > 3). *p < 0.05 by Fisher least signifi-
cant difference with Bonferroni correction for individual comparisons to GGG-NL and by analysis of variance for repeat length-
dependent differences among RAN reporters. (C) Localization of ASFMRP and ASFMRpolyP in transfected COS-7 cells stained
for FLAG (green). There was no change in distribution with increasing repeat size, and FLAG-positive inclusions were not
observed. DAPI (blue) was used to counterstain nuclei. NTC 5 Non-transfected control.
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With the validated antibodies, we looked for the pres-
ence of the ASFMR1 protein products in human brain tissue
from FXTAS patients. Preimmune sera for both antibodies
showed minimal background staining in both controls and
FXTAS cases (Figs 6C and 7C). When FXTAS tissues were
stained with ASFMRpolyP antibodies, we observed staining
in both FXTAS and control tissues in the hippocampus, cor-
tex, and cerebellum (see Fig 6). Staining was most intense in
the perinuclear region of neurons and was more robust in
most tissues in FXTAS cases than in controls. In addition,
ASFMRpolyP antibodies reliably stained intranuclear neuro-
nal aggregates in FXTAS tissues that were not observed in
control tissues. These aggregates were present in multiple
brain regions and were primarily neuronal. To better charac-
terize these aggregates, we performed coimmunofluorescence
with ASFMRpolyP and ubiquitin followed by confocal
FIGURE 3: Repeat-associated non-AUG (RAN) translation from CGC repeats in the arginine reading frame of ASFMR1. (A) West-
ern blot against FLAG in cells expressing the indicated ASMFRpolyR reporters. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a loading control. “noATG” indicates the ATG codon in the proline reading frame was removed. (B)
Nanoluciferase (NL) activity derived from the indicated constructs 24 hours after transfection. *p < 0.05 by Fisher least signifi-
cant difference with Bonferroni correction for individual comparisons to GGG-NL and by analysis of variance for repeat length-
dependent differences among RAN reporters. (C) FLAG staining of ASFMRpolyR constructs transfected into COS-7 cells.
ASFMRpolyR staining (green) shifted to the nucleus in the presence of the expanded CCG repeats and colocalized (arrows)
with the nucleolar marker nucleolin (red). DAPI (blue) was used to counterstain nuclei. NTC 5 no transfection control,
AS 5 antisense.
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microscopy. We observed numerous aggregates in neurons in
FXTAS cases that were both ubiquitin and ASFMRpolyP
positive.
To determine whether ASFMRpolyA also accumulated
in FXTAS cases, we performed similar immunohistochemical
and coimmunofluorescence studies. Like ASFMRpolyP,
ASFMRpolyA was found extensively in FXTAS, with the
greatest staining in the perinuclear regions of neurons in the
hippocampus and cortex (see Fig 7A). ASFMRpolyA stained
numerous intranuclear neuronal inclusions in multiple tis-
sues, and these inclusions were ubiquitin positive by coimmu-
nofluorescence (see Fig 7B, D).
Discussion
Aggregation of misfolded proteins is a hallmark in neuro-
degenerative disorders across a spectrum of etiologies.2,29
Identification of the misfolded protein species in each
disorder is a critical first step in elucidating the patho-
genic cascades responsible for neurodegeneration in that
condition. Here we demonstrate at least 2 new proteins
that accumulate in the neurodegenerative disorder
FXTAS: a polyproline-containing protein, ASFMRpolyP,
and a polyalanine-containing protein, ASFMRpolyA.
Using a series of reporter constructs, we further demon-
strate that both of these proteins can be generated
FIGURE 4: Repeat-associated non-AUG (RAN) translation from GCC repeats in the alanine reading frame of ASFMR1. (A) West-
ern blot against FLAG on lysates from COS-7 cells transfected with indicated ASFMRpolyA reporters. Red asterisks indicate
bands generated from initiation 30 to the repeat site but in the human sequence at a noncanonical start codon. “noATG” indi-
cates the ATG codon in the proline reading frame was absent. (B) Nanoluciferase (NL) activity from ASFMRpolyA constructs
compared to GGG-NL. *p < 0.05 by Fisher least significant difference with Bonferroni correction for individual comparisons to
GGG-NL and by analysis of variance for repeat length-dependent differences among RAN reporters. (C) Localization of ASFMR-
polyA (green) was primarily nuclear (arrows) compared to AUG-NL, which was cytoplasmic. DAPI (blue) was used to counter-
stain nuclei. NTC 5 no transfection control, GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase, AS 5 antisense.
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FIGURE 5: ASFMRpolyP and ASFMRpolyA antibody validation. (A, C) Western blots of constructs probed with FLAG or antibody
generated against ASFMRpolyP (a-ASpolyP; A), or against ASFMRpolyA (a-ASpolyA; C). Glyceraldehyde-3-phosphate dehydroge-
nase GAPDH was used as a loading control. (B, D) a-ASpolyP (red; B) recognized ASFMRPolyP but not AUG-nanoluciferase (NL) by
coimmunofluorescence. Similarly, a-ASpolyA (red; D) specifically recognized ASFMRpolyA but not AUG-NL. AS 5 antisense.
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through RAN translation, a recently described unconven-
tional form of initiation that occurs at multiple repeat
expansions, including the CGG repeat in the sense strand
of FMR1 in FXTAS.7
RAN translation has now been reported for 6 dif-
ferent repeats, with 3 derived from sense strand mRNA
transcripts (CAG, GGGGCC, and CGG repeats) and 3
derived primarily from antisense RNAs (CAG, CUG,
FIGURE 6: ASFMRpolyP accumulates in fragile X-associated
tremor/ataxia syndrome (FXTAS) brain tissue and intranu-
clear inclusions. (A) Control and FXTAS tissue from the indi-
cated brain regions stained with a-ASpolyP. Hematoxylin
(blue) was used as a counterstain to identify nuclei. In addi-
tion to strong perinuclear staining, nuclear aggregates
(arrows) were observed in FXTAS cases that were not seen
in control tissue. (B) Higher magnification of intranuclear
neuronal inclusions from the indicated brain regions from
FXTAS cases probed with a-ASpolyP. (C) Preimmune sera
for a-ASpolyP did not show staining in control or FXTAS
patient cortex. (D) Immunofluorescence of FXTAS hippocam-
pus showed colocalization of ASFMRpolyP (green) with
ubiquitin (red). DAPI (blue) was used to identify nuclei.
Scale bars 5 20 mm. CB 5 cerebellum; CTX 5 frontal cortex;
HIPP 5 hippocampus; MB 5 midbrain.
FIGURE 7: ASFMRpolyA repeat-associated non-AUG proteins
aggregate in fragile X-associated tremor/ataxia syndrome
(FXTAS) brain tissue. (A) Control and FXTAS tissue from the
indicated brain regions stained with a-ASpolyA. Hematoxylin
(blue) was used to identify nuclei. In addition to strong peri-
nuclear staining, nuclear aggregates (arrows) were observed
in FXTAS cases that were not seen in control tissue. (B) Higher
magnification of intranuclear neuronal inclusions from the
indicated brain regions from FXTAS cases probed with a-
ASpolyA. (C) Preimmune sera for a-ASpolyA did not show
specific staining in control or FXTAS patient cortex. (D) Coim-
munofluorescence on FXTAS hippocampus showed colocali-
zation of ASFMRpolyA (green) with ubiquitin (red). DAPI
(blue) was used to identify nuclei. Scale bars 5 20mm.
CB 5 cerebellum; CTX 5 frontal cortex; HIPP 5 hippocampus;
MB 5 midbrain.
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CCCCGG, and CCG repeats).5,7–13 All of these tran-
scripts are capable of forming strong secondary structures
in vitro, either RNA hairpins or G-quadruplexes, and the
ability to form these secondary structures appears impor-
tant to the process underlying RAN translation.5,27,30,31
That this CCG repeat resides within an open reading
frame is also consistent with previous data on CAG
repeats in Huntington disease and spinocerebellar ataxia
type 8, both of which allow RAN translation to occur in
all 3 potential reading frames within an open reading
frame.13 However, recent work on RAN translation at
CGG repeats supports a model for initiation that retains
a requirement for a 7-methylguanosine 50 cap on the
mRNA and ribosomal scanning,24 both of which superfi-
cially do not fit with a location of the repeat downstream
within an open reading frame and would require RAN
translation to bypass the canonical AUG start codon.
Thus, studies of initiation mechanisms at CCG repeats
in its native sequence context will be needed to delineate
how this atypical process occurs in human cells and how
it agrees or disagrees with findings at other repeats.
What role ASFMR1 mRNA-derived protein prod-
ucts have in FXTAS disease pathogenesis is also unclear.
Expression of CCG repeats in isolation in the 50 leader
sequence of GFP was sufficient to elicit toxicity in a Dro-
sophila model system.23 However, whether this toxicity
was driven by the repeats as RNA or as RAN-translated
proteins is not known. Polyalanine-containing proteins
and RAN products have previously been shown to be
toxic in isolation,5,32 and oculopharyngeal muscular dys-
trophy results from a polyalanine expansion in
polyadenylate-binding protein 2.33,34 In contrast, little is
known about the potential for polyproline or polyargi-
nine proteins to cause toxicity. Expression of dipeptide-
repeat–containing proteins generated from GGGGCC
repeats in C9orf72-containing arginine and/or proline
(glycine–arginine, proline–alanine, and proline–arginine
repeats) is toxic in cells and simple model systems when
expressed at high levels in the absence of a structured
RNA repeat.35–38 Moreover, the repetitive arginine ele-
ments target these proteins to the nucleolus,38 which we
also observe with ASFMRpolyR in cell transfection stud-
ies (Fig. 3b). Thus, defining both the potential for each
of these ASFMR1 RAN proteins to elicit toxicity in isola-
tion in model systems and their relative abundance in
FXTAS tissues will be important next steps in determin-
ing their potential roles in disease pathogenesis.
Our current study and antibodies cannot differenti-
ate between polyproline products generated by AUG-
initiated translation and RAN translation. Our cell-based
luciferase reporter assays suggest that removal of the
AUG start codon from the ASFMRP open reading frame
decreases the signal by approximately 10-fold (see Fig
2B). In addition, we observed staining in control tissues
with this antibody (although no staining of intranuclear
aggregates; see Fig 6A), but limited RAN products were
detected based on reporter assays at normal repeat sizes
(see Fig 2A, B). Thus, our antisense proline antibody is
likely staining both the AUG-initiation derived ASFMRP
protein and the RAN-derived ASFMRpolyP protein, and
both are potentially contributing to aggregation forma-
tion and toxicity.
In summary, we provide evidence for RAN transla-
tion at CCG repeats derived from an antisense FMR1
transcript. This work expands the list of potential patho-
genic species at play in fragile X-associated tremor/ataxia
syndrome and provides further support for noncanonical
translation of microsatellite repeat expansions in the
pathology of human neurodegenerative disease.
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